BidaskClub upgraded shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from a sell rating to a hold rating in a report issued on Wednesday.
Several other analysts have also recently commented on ACRS. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a buy rating in a report on Wednesday, August 9th. Jefferies Group LLC reissued a buy rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a report on Monday, July 31st. ValuEngine raised Aclaris Therapeutics from a sell rating to a hold rating in a report on Thursday, June 15th. Guggenheim reissued a buy rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, Zacks Investment Research cut Aclaris Therapeutics from a hold rating to a sell rating in a report on Friday, May 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $39.00.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded down 1.09% on Wednesday, reaching $26.30. The company’s stock had a trading volume of 70,057 shares. Aclaris Therapeutics has a 1-year low of $19.54 and a 1-year high of $33.25. The company’s market capitalization is $703.16 million. The stock has a 50-day moving average price of $27.77 and a 200-day moving average price of $27.95.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.12. On average, equities research analysts forecast that Aclaris Therapeutics will post ($3.10) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.com-unik.info/2017/08/17/aclaris-therapeutics-inc-acrs-upgraded-by-bidaskclub-to-hold.html.
In other news, Director Andrew N. Schiff acquired 108,601 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The stock was purchased at an average cost of $23.02 per share, with a total value of $2,499,995.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 16.30% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Citigroup Inc. boosted its position in shares of Aclaris Therapeutics by 171.8% in the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 2,726 shares in the last quarter. UBS Group AG boosted its position in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 1,681 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Aclaris Therapeutics by 98.3% in the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 2,605 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Aclaris Therapeutics by 269.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 3,500 shares in the last quarter. Finally, First Mercantile Trust Co. boosted its position in shares of Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 600 shares in the last quarter. 88.71% of the stock is owned by hedge funds and other institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
What are top analysts saying about Aclaris Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc. and related companies.